GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan
The industry looks set to bring the first vaccine for RSV to market in the coming year. But, which companies are leading the race, and why it would mark an important development for global health?
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh